An upregulation of genes involved in the immune response, such as proinflammatory cytokines and cytotoxic mediators is observed in MMR deficiency tumors, resulting in an increased secretion of soluble mediators in the tumor microenvironment with the subsequent activation of the PD-1 pathway 86. The gene discussed is PDCD1; the disease is mismatch repair cancer syndrome 1.